Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size.

Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, Nagy-Davidescu G, Dreier B, Schibli R, Binz HK, Waibel R, Plückthun A.

Cancer Res. 2010 Feb 15;70(4):1595-605. doi: 10.1158/0008-5472.CAN-09-2724. Epub 2010 Feb 2.

2.

Affinity and avidity in antibody-based tumor targeting.

Rudnick SI, Adams GP.

Cancer Biother Radiopharm. 2009 Apr;24(2):155-61. doi: 10.1089/cbr.2009.0627. Review.

3.

Engineered affinity proteins for tumour-targeting applications.

Friedman M, Ståhl S.

Biotechnol Appl Biochem. 2009 May;53(Pt 1):1-29. doi: 10.1042/BA20080287. Review.

PMID:
19341363
4.

High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy.

Zhang Y, Pastan I.

Clin Cancer Res. 2008 Dec 15;14(24):7981-6. doi: 10.1158/1078-0432.CCR-08-0324. Review.

5.

Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids.

Ackerman ME, Pawlowski D, Wittrup KD.

Mol Cancer Ther. 2008 Jul;7(7):2233-40. doi: 10.1158/1535-7163.MCT-08-0067.

6.

Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.

Thurber GM, Schmidt MM, Wittrup KD.

Adv Drug Deliv Rev. 2008 Sep;60(12):1421-34. doi: 10.1016/j.addr.2008.04.012. Epub 2008 Apr 24. Review.

7.

Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts.

Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI.

Clin Cancer Res. 2008 Apr 1;14(7):2171-9. doi: 10.1158/1078-0432.CCR-07-4465. Erratum in: Clin Cancer Res. 2008 May 1;14(9):2893.

8.

Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.

Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM.

J Immunol. 2007 Sep 1;179(5):2815-23.

9.

Theoretic criteria for antibody penetration into solid tumors and micrometastases.

Thurber GM, Zajic SC, Wittrup KD.

J Nucl Med. 2007 Jun;48(6):995-9. Epub 2007 May 15.

10.

PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting.

Kubetzko S, Balic E, Waibel R, Zangemeister-Wittke U, Plückthun A.

J Biol Chem. 2006 Nov 17;281(46):35186-201. Epub 2006 Sep 8.

11.

Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action.

Lammerts van Bueren JJ, Bleeker WK, Bøgh HO, Houtkamp M, Schuurman J, van de Winkel JG, Parren PW.

Cancer Res. 2006 Aug 1;66(15):7630-8.

12.

Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers.

Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF 3rd, Houston LL, Huston JS, Weiner LM.

Clin Cancer Res. 2006 Mar 1;12(5):1599-605.

13.

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.

Austin CD, De Mazière AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH.

Mol Biol Cell. 2004 Dec;15(12):5268-82. Epub 2004 Sep 22.

14.
15.

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM.

Cancer Res. 2001 Jun 15;61(12):4750-5.

16.

Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.

Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM.

Cancer Res. 1998 Feb 1;58(3):485-90.

17.

Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.

Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD.

J Mol Biol. 1996 Nov 8;263(4):551-67.

PMID:
8918938
18.

Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.

Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, King DJ, Haines AM, Hamann P, Hinman L, Shochat D, Bernstein ID.

Cancer Res. 1996 May 1;56(9):2123-9.

19.

Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection.

Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, Weiner LM, Marks JD.

J Mol Biol. 1996 Jan 12;255(1):28-43.

PMID:
8568873
20.

Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells.

Mattes MJ, Griffiths GL, Diril H, Goldenberg DM, Ong GL, Shih LB.

Cancer. 1994 Feb 1;73(3 Suppl):787-93.

Supplemental Content

Support Center